Intensity Therapeutics Achieves Compliance with Nasdaq Minimum Bid Price Requirements

Intensity Therapeutics Regains Compliance with Nasdaq

On March 6, 2026, Intensity Therapeutics, Inc. (Nasdaq: INTS), a prominent late-stage clinical biotechnology firm, announced its recent compliance with Nasdaq's Listing Rule 5550(a)(2), which stipulates a minimum bid price of $1.00 per share. This achievement comes after the company maintained a closing stock price at or above the required threshold for ten consecutive business days, specifically from February 19, 2026, to March 4, 2026.

About Intensity Therapeutics

Intensity Therapeutics is focused on pioneering innovative intratumoral cancer therapies. Their approach, built around proprietary non-covalent conjugation technology, aims to effectively eradicate tumors while enhancing immune recognition of cancer cells. The company has seen promising results from its clinical trials which employ their lead product candidate, INT230-6.

INT230-6 is designed for direct intratumoral injection and leverages a unique platform known as DfuseRx℠. It incorporates a combination of two established anti-cancer agents, cisplatin and vinblastine sulfate, along with a diffusion and cell penetration enhancer molecule. This combination enables the drug to permeate the tumor environment effectively, significantly improving local control of the disease and assisting in engaging the immune system in combating cancer. Notably, INT230-6 has the potential to invoke anti-tumor effects without the immunosuppression that often accompanies traditional systemic chemotherapy.

Recent Clinical Developments

Intensity has already conducted several clinical studies involving over 200 patients. The firm is also planning to move forward with its Phase 3 clinical trial, named the INVINCIBLE-3 Study, to investigate the efficacy of INT230-6 compared to standard care options in patients with soft tissue sarcoma.
Moreover, Intensity has partnered with the Swiss Cancer Group to evaluate the effects of INT230-6 in presurgical triple-negative breast cancer patients in their INVINCIBLE-4 Study. Clinical trials are crucial as they provide the necessary data to assess both the safety and effectiveness of novel therapies.

Despite the positive compliance news from Nasdaq, Intensity cautions that various future uncertainties could impact its business trajectory. The management’s optimistic projections regarding upcoming milestones, cash runway, and overall business strategy remain contingent upon a myriad of factors affecting clinical trials, funding, and regulatory approvals.

The Road Ahead

With the regained compliance, Intensity Therapeutics is poised to further its ambitious agenda in the oncology sector. Their innovative approaches and technology are aimed at redefining cancer treatment. As they continue to conduct significant clinical studies, the potential for transforming the landscape of cancer treatment remains high. The company encourages interested parties to learn more about its pioneering strategies and ongoing research by visiting their official website.

As Intensity Therapeutics forges ahead, stakeholders and investors alike will be keenly monitoring developments that indicate the company’s direction and ability to leverage its advancements in cancer therapy to bring about meaningful patient outcomes.